Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok AS.
Division of Gastroenterology, University of Michigan Medical Center, 1500 East Medical Center Drive, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109-0362, USA.
The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.
Publication Types:
PMID: 16517902 [PubMed - indexed for MEDLINE]PMCID: PMC1393162